MA55557A - Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations - Google Patents

Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations

Info

Publication number
MA55557A
MA55557A MA055557A MA55557A MA55557A MA 55557 A MA55557 A MA 55557A MA 055557 A MA055557 A MA 055557A MA 55557 A MA55557 A MA 55557A MA 55557 A MA55557 A MA 55557A
Authority
MA
Morocco
Prior art keywords
orally administered
solid forms
lactamase inhibitor
administered beta
beta
Prior art date
Application number
MA055557A
Other languages
English (en)
Inventor
Steven A Boyd
Christopher J Burns
Stephen M Condon
Yijun Deng
Eugen F Mesaros
Lawrence Rosen
Robert Simpson
Robert E Lee Trout
Allison L Zulli
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of MA55557A publication Critical patent/MA55557A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055557A 2019-04-02 2020-04-01 Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations MA55557A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962828349P 2019-04-02 2019-04-02

Publications (1)

Publication Number Publication Date
MA55557A true MA55557A (fr) 2022-02-09

Family

ID=72666564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055557A MA55557A (fr) 2019-04-02 2020-04-01 Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations

Country Status (14)

Country Link
US (1) US20220194964A1 (fr)
EP (1) EP3946364B1 (fr)
JP (1) JP2022529212A (fr)
KR (1) KR20210146979A (fr)
CN (1) CN113905741B (fr)
AU (1) AU2020256179A1 (fr)
BR (1) BR112021019656A2 (fr)
CA (1) CA3135614A1 (fr)
EA (1) EA202192669A1 (fr)
IL (1) IL286850A (fr)
MA (1) MA55557A (fr)
SG (1) SG11202110683WA (fr)
TW (1) TW202102230A (fr)
WO (1) WO2020205932A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943204B1 (fr) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Inhibiteurs de bêta-lactamase
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP3630783A4 (fr) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Inhibiteurs protéiques de liaison à la pénicilline
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
CN113382713A (zh) * 2018-11-29 2021-09-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物及其用途
KR20230062075A (ko) 2021-10-29 2023-05-09 코웨이 주식회사 제빙용 증발기
WO2025111328A1 (fr) 2023-11-21 2025-05-30 VenatoRx Pharmaceuticals, Inc. Complexe de coordination de citrate d'un inhibiteur de bêta-lactamase administré par voie orale et ses utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
WO2011073845A1 (fr) * 2009-12-16 2011-06-23 Pfizer Inc. Dérivés d'acide hydroxamique à liaison n, utiles comme agents antibactériens
CA2864669A1 (fr) * 2012-02-16 2013-08-22 Rqx Pharmaceuticals, Inc. Antibiotiques a peptide lineaire
WO2014057436A2 (fr) * 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Conjugué anticancéreux
CN105026407B (zh) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
KR20150103269A (ko) * 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
PT3154989T (pt) * 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN108472284A (zh) * 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (fr) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
CN113382713A (zh) * 2018-11-29 2021-09-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物及其用途

Also Published As

Publication number Publication date
SG11202110683WA (en) 2021-10-28
EA202192669A1 (ru) 2022-03-01
TW202102230A (zh) 2021-01-16
IL286850A (en) 2021-10-31
KR20210146979A (ko) 2021-12-06
BR112021019656A2 (pt) 2022-01-18
CA3135614A1 (fr) 2020-10-08
CN113905741A (zh) 2022-01-07
US20220194964A1 (en) 2022-06-23
CN113905741B (zh) 2024-12-13
EP3946364A4 (fr) 2023-01-18
EP3946364A1 (fr) 2022-02-09
EP3946364B1 (fr) 2025-11-19
WO2020205932A1 (fr) 2020-10-08
AU2020256179A1 (en) 2021-11-18
JP2022529212A (ja) 2022-06-20

Similar Documents

Publication Publication Date Title
EP3946364A4 (fr) Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations
EP3972978A4 (fr) Inhibiteurs de kras g12c et leurs utilisations
EP4267134A4 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de kras g12c et utilisations d'un inhibiteur de kras g12c pour le traitement de cancers
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
EP3829554A4 (fr) Compositions pharmaceutiques "solides auto-émulsifiantes
EP4087406A4 (fr) Compositions vésiculaires pour une administration par voie orale
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
EP4228634A4 (fr) Inhibition de l'intégrine humaine a4b7
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3980046A4 (fr) Mutant g12v de kras se liant à jak1, inhibiteurs, compositions pharmaceutiques et procédés associés
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
EP3616696A4 (fr) Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
MX390625B (es) Inhibidores selectivos de jak1.
EP3938369A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
EP3893891A4 (fr) Formes solides d'un inhibiteur de cd73 et leur utilisation
EP3902542A4 (fr) Inhibiteurs de la kinase dépendante des cyclines 7 et leurs utilisations
EP3846793A4 (fr) Inhibiteurs d'eif4e et leurs utilisations
EP3975999A4 (fr) Formulations de phosphatase alcaline et leurs utilisations
EP4003335A4 (fr) Inhibiteurs de kinase 7 dépendante des cyclines et leurs utilisations
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
EP3976009A4 (fr) Inhibiteurs de bax et leurs utilisations
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
MA53010A (fr) Formulations d'un inhibiteur de axl/mer